《5、消化系统肿瘤消化系统肿瘤 (15).pdf》由会员分享，可在线阅读，更多相关《5、消化系统肿瘤消化系统肿瘤 (15).pdf（5页珍藏版）》请在taowenge.com淘文阁网|工程机械CAD图纸|机械工程制图|CAD装配图下载|SolidWorks_CaTia_CAD_UG_PROE_设计图分享下载上搜索。
1、 Journal of Clinical Oncology List of Issues Volume 39,Issue 15_suppl Meeting Abstract|2021 ASCO Annual Meeting IGASTROINTESTINAL CANCERGASTROESOPHAGEAL,PANCREATIC,ANDHEPATOBILIARYLenvatinib plus toripalimab as first-linetreatment for advanced intrahepaticRights&PermissionsOPTIONS&TOOLSExport Citati
2、onTrack CitationAdd To FavoritesCOMPANION ARTICLESADVERTISEMENTLog InSubmitE-AlertsCartOpenAthens/Shibboleth MENU Article ToolsADVERTISEMENTcholangiocarcinoma:A single-arm,phase 2trial.Zhou Jian,Jia Fan,Guo-Ming Shi,Xiao-Yong Huang,Dong Wu,Fei Liang,.Show MoreAbstract Disclosures4099Background:Lenva
3、tinib monotherapy andlenvatinib plus PD-1 antibody have shown someclinical benefit for advanced intrahepaticcholangiocarcinoma(ICC)in the second-linesetting.Our study assesses the role of lenvatinibplus toripalimab(PD-1 antibody)for advanced ICCpatients as the first line therapy.Methods:Patients(pts
4、)with locally advanced or metastaticICC received 12 mg/day(Body Weight 60 kg)or 8mg/day(Body Weight 60 kg)oral lenvatinib dailyplus 240 mg intravenous toripalimab every 3No companion articlesARTICLE CITATIONDOI:10.1200/JCO.2021.39.15_suppl.4099Journal of Clinical Oncology 39,no.15_suppl(May 20,2021)
5、4099-4099.Published online May 28,2021.ADVERTISEMENTEmployer:Merritt HawkinsApply for this job Employer:Potomac Oncology&HematologyApply for this job Hematology-Oncology OpportunityJust Outside of ChicagoRockford,Illinois N/AA reputable integrated health system seekinga board-certified or board-elig
6、iblehematologist-oncologist to join its team.Oncology&Hematology AssociatePositionRockville,Maryland Competitive SalaryThis position offers a competitive base salary,a comprehensive benefits package,exceptional productivity incentives,and apartnership track.Hematology/Oncology-at the Beach inLow Tax
7、 Delaware!Delaware(US);Family-oriented resort area inbeautiful south coastal DelawareAbstractADVERTISEMENTweeks.The primary endpoint was objectiveresponse rate(ORR)and evaluated according toResponse Evaluation Criteria In Solid Tumorsversion 1.1(RECIST v1.1).Secondary endpointsincluded safety,progre
8、ssion-free survival(PFS)and overall survival(OS).Treatment continueduntil confirmed disease progression,unacceptabletoxicity,or voluntary withdrawal.This trial isregistered with ClinicalTrials.gov(NCT04361331).Results:From March 2020 to Sep.2020,31pathologically confirmed advanced ICC pts with amean
9、 age of 58.4(range,25-73)years,including18 women(58.0%),were enrolled at ZhongshanHospital,Fudan University.At the end of lastfollow-up(February 10,2021),the ORR was 32.3%(10/31;95%CI:16.7%-51.4%)and the diseasecontrol rate(DCR)was 74.2%(23/31;95%CI:55.4%-88.1%).Median follow-up was 6.9 months.Two p
10、ts with locally advanced disease were down-staged and then underwent resection.Theyremained disease-free survival at the end of lastfollow-up.11 pts exerted disease progression and7 pts died.The median PFS and OS have not beenADVERTISEMENTADVERTISEMENTreached.Median duration of response(DOR)hasnot b
11、een reached and responses were ongoing in9/10(90.0%)pts at data cutoff.6-months OS ratewas 87.1%.No grade 5 adverse event(AE)wasobserved in present study.32.3%(10/31)of ptsexperienced Grade 3 or higher AEs and 1 ptsdiscontinued the treatment owing to severefatigue.Conclusions:As the first-line thera
12、py,lenvatinib plus toripalimab provided promisingefficacy with reasonable safety profile in advancedICC patients.It offered an alternative treatmentfor advanced ICC who cannot tolerategemcitabine-based chemotherapy.Clinical trialinformation:NCT04361331.2021 by American Society of Clinical OncologyRe
13、search Sponsor:NoneQUICK LINKSContentResourcesASCO FAMILY OF SITESJournalsEducationADVERTISEMENTNewest Articles Archive Meeting AbstractsJournal InformationAbout Editorial Roster Contact Us PermissionsAuthors Reviewers Subscribers Institutions AdvertisersSubmit Your ManuscriptSubscribe to this Journ
14、alJournal of Clinical Oncology JCO Oncology Practice JCO Global Oncology JCO Clinical Cancer Informatics JCO Precision OncologyPublicationsASCO Educational Book ASCO Daily News ASCO Connection The ASCO Post ASCO eLearning ASCO Meetings Cancer.NetOther SitesASCO.org ASCO Author Services ASCO Career Center CancerLinQ Conquer Cancer Foundation TAPUR Study American Society of Clinical Oncology2318 Mill Road,Suite 800,Alexandria,VA 22314 2021 American Society of Clinical Oncology Terms of Use|Privacy Policy|CookiesADVERTISEMENT